Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
MET642 in patients with NASH
NCT04773964Phase 2Completed
- Sponsor
- Metacrine, Inc.
- Start
- Mar 2021
- Primary completion
- Dec 2022
- Modality
- Small Molecules
- Countries
- 1
01
Overview
A Phase 2 trial of omesdafexor in Nonalcoholic steatohepatitis (NASH), sponsored by Metacrine, Inc.. Started Mar 2021; status: completed.
02
Drugs
omesdafexor
03
Conditions
Nonalcoholic steatohepatitis (NASH)
Beyond the preview
Go deeper on NCT04773964.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04773964.